Margaret Kaczor
Stock Analyst at William Blair
(0.54)
# 4,103
Out of 5,182 analysts
25
Total ratings
35.71%
Success rate
-19%
Average return
Main Sectors:
Stocks Rated by Margaret Kaczor
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PEN Penumbra | Downgrades: Market Perform | n/a | $325.99 | - | 1 | Jan 15, 2026 | |
| STAA STAAR Surgical Company | Downgrades: Market Perform | n/a | $26.71 | - | 2 | Feb 12, 2025 | |
| CVRX CVRx, Inc. | Upgrades: Outperform | n/a | $7.48 | - | 3 | Jan 14, 2025 | |
| CBLL CeriBell | Initiates: Outperform | n/a | $20.80 | - | 1 | Nov 5, 2024 | |
| STIM Neuronetics | Downgrades: Market Perform | n/a | $1.64 | - | 4 | Aug 12, 2024 | |
| INGN Inogen | Upgrades: Outperform | n/a | $7.35 | - | 5 | Feb 15, 2024 | |
| SKIN SkinHealth Systems | Downgrades: Market Perform | n/a | $0.84 | - | 2 | Nov 14, 2023 | |
| DVA DaVita | Downgrades: Market Perform | n/a | $150.07 | - | 2 | Sep 11, 2019 | |
| MDT Medtronic | Assumes: Market Perform | n/a | $81.90 | - | 1 | Jun 6, 2018 | |
| ABT Abbott Laboratories | Upgrades: Outperform | n/a | $93.86 | - | 3 | Jan 25, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $59.32 | - | 1 | Apr 27, 2017 |
Penumbra
Jan 15, 2026
Downgrades: Market Perform
Price Target: n/a
Current: $325.99
Upside: -
STAAR Surgical Company
Feb 12, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $26.71
Upside: -
CVRx, Inc.
Jan 14, 2025
Upgrades: Outperform
Price Target: n/a
Current: $7.48
Upside: -
CeriBell
Nov 5, 2024
Initiates: Outperform
Price Target: n/a
Current: $20.80
Upside: -
Neuronetics
Aug 12, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $1.64
Upside: -
Inogen
Feb 15, 2024
Upgrades: Outperform
Price Target: n/a
Current: $7.35
Upside: -
SkinHealth Systems
Nov 14, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $0.84
Upside: -
DaVita
Sep 11, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $150.07
Upside: -
Medtronic
Jun 6, 2018
Assumes: Market Perform
Price Target: n/a
Current: $81.90
Upside: -
Abbott Laboratories
Jan 25, 2018
Upgrades: Outperform
Price Target: n/a
Current: $93.86
Upside: -
Apr 27, 2017
Initiates: Outperform
Price Target: n/a
Current: $59.32
Upside: -